scholarly journals Safety and Efficacy of the 10-Day Melarsoprol Schedule for the Treatment of Second Stage Rhodesiense Sleeping Sickness

2012 ◽  
Vol 6 (8) ◽  
pp. e1695 ◽  
Author(s):  
Irene Kuepfer ◽  
Caecilia Schmid ◽  
Mpairwe Allan ◽  
Andrew Edielu ◽  
Emma P. Haary ◽  
...  
Keyword(s):  
Sleeping Sickness ◽  
Safety And Efficacy ◽  
Second Stage

scholarly journals New Treatment Option for Second-Stage African Sleeping Sickness: In Vitro and In Vivo Efficacy of Aza Analogs of DB289

2009 ◽  
Vol 53 (10) ◽  
pp. 4185-4192 ◽  
Author(s):  
Tanja Wenzler ◽  
David W. Boykin ◽  
Mohamed A. Ismail ◽  
James Edwin Hall ◽  
Richard R. Tidwell ◽  
...  
Keyword(s):  
Sleeping Sickness ◽  
African Sleeping Sickness ◽  
African Trypanosomes ◽  
Second Stage ◽  
Resistant Lines ◽  
New Treatment ◽  
Toxic Drugs ◽  
Further Development

ABSTRACT African sleeping sickness is a fatal parasitic disease, and all drugs currently in use for treatment have strong liabilities. It is essential to find new, effective, and less toxic drugs, ideally with oral application, to control the disease. In this study, the aromatic diamidine DB75 (furamidine) and two aza analogs, DB820 and DB829 (CPD-0801), as well as their methoxyamidine prodrugs and amidoxime metabolites, were evaluated against African trypanosomes. The active parent diamidines showed similar in vitro profiles against different Trypanosoma brucei strains, melarsoprol- and pentamidine-resistant lines, and a P2 transporter knockout strain (AT1KO), with DB75 as the most trypanocidal molecule. In the T. b. rhodesiense strain STIB900 acute mouse model, the aza analogs DB820 and DB829 demonstrated activities superior to that of DB75. The aza prodrugs DB844 and DB868, as well as two metabolites of DB844, were orally more potent in the T. b. brucei strain GVR35 mouse central nervous system (CNS) model than DB289 (pafuramidine maleate). Unexpectedly, the parent diamidine DB829 showed high activity in the mouse CNS model by the intraperitoneal route. In conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further development of a second-stage African sleeping sickness drug.

scholarly journals In VitroandIn VivoEvaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness

2014 ◽  
Vol 58 (8) ◽  
pp. 4452-4463 ◽  
Author(s):  
Tanja Wenzler ◽  
Sihyung Yang ◽  
Donald A. Patrick ◽  
Olivier Braissant ◽  
Mohamed A. Ismail ◽  
...  
Keyword(s):  
Parasite Clearance ◽  
Sleeping Sickness ◽  
Cross Resistance ◽  
Tsetse Flies ◽  
Central Nervous System Infections ◽  
African Sleeping Sickness ◽  
Content Type ◽  
Second Stage ◽  
Trypanosoma Brucei Gambiense

ABSTRACTAfrican sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness. Thein vitrotime to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010 than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the testedTrypanosoma brucei gambienseisolates from melarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diamidines for the treatment of second-stage African sleeping sickness.

scholarly journals Second stage African Trypanosomiasis presented as Non Convulsive Status Epilepticus

2021 ◽  
Author(s):  
Etedal Ahmed A. Ibrahim ◽  
Mohammed Gasm Elseed M Elmahal ◽  
Khabab Abbasher Hussien Mohamed Ahmed ◽  
Mohammed Eltahier Abdalla Omer
Keyword(s):  
Status Epilepticus ◽  
Human African Trypanosomiasis ◽  
South Sudan ◽  
Sleeping Sickness ◽  
Common Disease ◽  
Convulsive Status Epilepticus ◽  
African Trypanosomiasis ◽  
Second Stage

Abstract Human African Trypanosomiasis also known as sleeping sickness is a common disease in South Sudan. There are two recognized sstage, The early hemolymphatic stage and The late encephalitic stage when the CNS is involved specially with Gambians infection, broad neurologic spectrum has been reported such as psychiatric, motor, sensory.

scholarly journals Randomized, Controlled Trial of Treatments for Second‐Stage Sleeping Sickness

2007 ◽  
Vol 196 (4) ◽  
pp. 650-651 ◽  
Author(s):  
Charles Jonathan Woodrow ◽  
Paulo Manuel Abel ◽  
Sanjeev Krishna
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Sleeping Sickness ◽  
Second Stage ◽  
Randomized Controlled

scholarly journals Second stage African Trypanosomiasis presented as Non Convulsive Status Epilepticus

2021 ◽  
Author(s):  
Eetadal Ibrahim ◽  
Mohammed Gasm Elseed M Elmahal ◽  
Khabab Mohamed Ahmed ◽  
Mohammed Omer
Keyword(s):  
Status Epilepticus ◽  
Human African Trypanosomiasis ◽  
South Sudan ◽  
Sleeping Sickness ◽  
Common Disease ◽  
Convulsive Status Epilepticus ◽  
African Trypanosomiasis ◽  
Second Stage

Human African Trypanosomiasis also known as sleeping sickness is a common disease in South Sudan. There are two recognized sstage, The early hemolymphatic stage and The late encephalitic stage when the CNS is involved specially with Gambians infection, broad neurologic spectrum has been reported such as psychiatric, motor, sensory.

Sign in / Sign up

Export Citation Format

Share Document